{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:30:59Z","timestamp":1787956259342,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ \\u2013 DRO-FNOs\/2025"],"award-info":[{"award-number":["MH CZ \\u2013 DRO-FNOs\/2025"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106591","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:06:43Z","timestamp":1750169203000},"page":"106591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare"],"prefix":"10.1016","volume":"101","author":[{"given":"Moskorova","family":"Denisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-754X","authenticated-orcid":false,"given":"Kacirova","family":"Ivana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hradilek","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matlak","family":"Patrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brozmanova","family":"Hana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sistik","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koristkova","family":"Blanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grundmann","family":"Milan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.msard.2025.106591_bib0001","first-page":"609","article-title":"Non-late-onset neutropenia following treatment of multiple sclerosis with ocrelizumab","volume":"36","author":"Alba Su\u00e1rez","year":"2021","journal-title":"Neurologia"},{"key":"10.1016\/j.msard.2025.106591_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaneurol.2019.4443","article-title":"Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy","volume":"77","author":"Birnbaum","year":"2020","journal-title":"JAMa Neurol."},{"issue":"22","key":"10.1016\/j.msard.2025.106591_bib0004","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","volume":"94","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106591_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102802","article-title":"Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis","volume":"49","author":"Capasso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106591_bib0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.msard.2025.106591_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1079\/BJN19910073","article-title":"Body mass index as a measure of body fatness: age- and sex-specific prediction formulas","volume":"65","author":"Deurenberg","year":"1991","journal-title":"Br. J. Nutr."},{"issue":"Suppl. 1","key":"10.1016\/j.msard.2025.106591_bib0008","first-page":"e179","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions [abstract]","volume":"131","author":"Derfuss","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2025.106591_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577505","article-title":"Natalizumab induced blood eosinophilia: a retrospective pharmacovigilance cohort study and review of the literature","volume":"353","author":"Diem","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0010","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0011","article-title":"A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis","volume":"6","author":"Evertsson","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"2","key":"10.1016\/j.msard.2025.106591_bib0012","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1212\/NXI.0000000000000940","article-title":"Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS","volume":"8","author":"Fern\u00e1ndez-Velasco","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2025.106591_bib0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go?","volume":"39","author":"Furst","year":"2009","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0014","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.msard.2025.106591_bib0015","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"16","key":"10.1016\/j.msard.2025.106591_bib0016","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106591_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106591_bib0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jmsacl.2022.07.004","article-title":"Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry","volume":"25","author":"Hallin","year":"2022","journal-title":"J. Mass Spectrom. Adv. Clin. Lab."},{"key":"10.1016\/j.msard.2025.106591_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104015","article-title":"Ocrelizumab-related neutropenia: effects of age, sex, and bodyweight using the FDA Adverse Event Reporting System (FAERS)","volume":"65","author":"Hammer","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106591_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106246","article-title":"Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis","volume":"93","author":"Kacirova","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106591_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"12","key":"10.1016\/j.msard.2025.106591_bib0022","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2174\/0118715273302279240529104919","article-title":"Analysis of concentrations of monomethyl fumarate in patients with multiple sclerosis: result from routine health care","volume":"23","author":"Kusnirikova","year":"2024","journal-title":"CNS. Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.msard.2025.106591_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122910","article-title":"Serum teriflunomide concentrations in routine multiple sclerosis therapy: a cross-sectional pilot study","volume":"458","author":"Kusnirikova","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"17_suppl_1","key":"10.1016\/j.msard.2025.106591_bib0024","article-title":"Body mass index not associated with MS relapse after anti-CD20 therapy (P2-6.001)","volume":"102","author":"Loeffler","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1590\/S0004-282X1981000400003","article-title":"Cerebrospinal fluid eosinophils in inflammatory processes of the central nervous system and its coverings","volume":"39","author":"Machado","year":"1981","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106591_bib0026","article-title":"A liquid chromatography-tandem mass spectrometry method for determination of ocrelizumab in serum of patients with multiple sclerosis","author":"Matlak","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.msard.2025.106591_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.msard.2025.106591_bib0028","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1002\/acn3.52229","article-title":"Subcutaneous ocrelizumab in multiple sclerosis: results of the phase 1b OCARINA I study","volume":"11","author":"Newsome","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106591_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102058","article-title":"Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy","volume":"42","author":"Nylund","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106591_bib0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/13524585241245296","article-title":"Extended interval dosing with ocrelizumab in multiple sclerosis","volume":"30","author":"Novak","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106591_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104090","article-title":"Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: a retrospective case series and a systematic review of reported cases","volume":"68","author":"Rossi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0032","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000321072","article-title":"Analysis of past and present methods of measuring and estimating body surface area and the resulting evaluation of its doubtful suitability to universal application","volume":"30","author":"Ruggieri","year":"2010","journal-title":"Blood Purif."},{"key":"10.1016\/j.msard.2025.106591_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/5383099","article-title":"The plasticity of immune cell response complicates dissecting the underlying pathology of multiple sclerosis","volume":"2024","author":"Sarkar","year":"2024","journal-title":"J. Immunol. Res."},{"issue":"8","key":"10.1016\/j.msard.2025.106591_bib0034","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106591_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102186","article-title":"BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab","volume":"43","author":"Signoriello","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106591_bib0037","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/antib8040056","article-title":"Understanding inter-individual variability in monoclonal antibody disposition","volume":"8","author":"Thomas","year":"2019","journal-title":"Antibodies"},{"issue":"6","key":"10.1016\/j.msard.2025.106591_bib0038","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/jnnp-2022-330793","article-title":"Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis","volume":"94","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2025.106591_bib0039","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106591_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ana.26534","article-title":"Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis","volume":"93","author":"van Kempen","year":"2023","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106591_bib0041","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106591_bib0042","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106591_bib0043","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/jpm11050335","article-title":"Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis","volume":"11","author":"Zarzuelo","year":"2021","journal-title":"J. Pers. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:29:26Z","timestamp":1778840966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":42,"alternative-id":["S2211034825003335"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106591","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106591"}}